Gene · 4543
MTNR1A: melatonin receptor 1A
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. MTNR1A: melatonin receptor 1A. Genes, record 4543. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/4543
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P48039 | Melatonin receptor type 1A | 350 | 8 | Ensembl, GeneID, HGNC |
Source UniProt
Patents25
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 53143 | P48039 | Espacenet |
| WO 2025259600 A2 | 2025-12-18 | 13 | P48039 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 2744 | P48039 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 2744 | P48039 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 50191 | P48039 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 3406 | P48039 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 153162 | P48039 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 7082 | P48039 | Espacenet |
| US 10772934 B2 | 2020-09-15 | 1082 | P48039 | Espacenet |
| US 10533225 B2 | 2020-01-14 | 149 | P48039 | Espacenet |
1 to 10 of 25
See all 25 patentsDrugs5
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AGOMELATINE | CHEMBL10878 | Melatonin receptor agonist | AGONIST | ChEMBL |
| MELATONIN | CHEMBL45 | Melatonin receptor agonist | AGONIST | ChEMBL |
| PIROMELATINE | CHEMBL4297523 | Melatonin receptor agonist | AGONIST | ChEMBL |
| RAMELTEON | CHEMBL1218 | Melatonin receptor agonist | AGONIST | ChEMBL |
| TASIMELTEON | CHEMBL2103822 | Melatonin receptor agonist | AGONIST | ChEMBL |
Trials264
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07576764 | MELATONIN | PHASE3 | ClinicalTrials.gov | |
| NCT07553143 | MELATONIN | ClinicalTrials.gov | ||
| NCT07549295 | MELATONIN | PHASE1 | ClinicalTrials.gov | |
| NCT07472075 | MELATONIN | PHASE2 | ClinicalTrials.gov | |
| NCT07418554 | MELATONIN | PHASE3 | ClinicalTrials.gov | |
| NCT07375693 | MELATONIN | PHASE2 | ClinicalTrials.gov | |
| NCT07369284 | MELATONIN | PHASE2 | ClinicalTrials.gov | |
| NCT07344467 | MELATONIN | ClinicalTrials.gov | ||
| NCT07343947 | MELATONIN | ClinicalTrials.gov | ||
| NCT07334197 | MELATONIN | ClinicalTrials.gov |
1 to 10 of 264
See all 264 trialsNIH grants371
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | MTNR1A papers | Newest fiscal year |
|---|---|---|---|
| P30EY006360 | P30-Core Grant for Vision Research | 4 | 2025 |
| I01BX004293 | CYP11A1-derived secosteroids as therapeutic agents in UVB induced skin cancer | 3 | 2025 |
| R01AR073004 | Mechanism of action and function of novel secosteroid 20(OH)D3 in the skin | 3 | 2025 |
| R01MH112205 | Molecular Details of Psychoactive Drug Actions | 3 | 2025 |
| R35GM127086 | Structural Biology Of G Protein-Coupled Receptors | 3 | 2025 |
| P30EY001583 | P30 Core Grant For Vision Research | 2 | 2025 |
| R35GM119518 | pH regulation of cell surface receptors | 2 | 2025 |
| R35GM122481 | Development and Testing of New Computational Methods for Ligand Discovery and Mechanism | 2 | 2025 |
| T32CA009110 | Training in Areas Fundamental to Cancer Research | 2 | 2025 |
| IK6BX004601 | BLR&D Research Career Scientist Award | 1 | 2025 |
1 to 10 of 371Source NIH's project files
See all 371 nih grantsPapers747
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
Ferroptosis-driven stromal immune evasion and melatonin receptor suppression as novel predictive biomarkers of immunotherapy response in oral squamous cell carcinoma: a single-cell transcriptomic study. | Front Genet | 2026 | 42707754 | PubTator, text mining | PubMed |
| Impact of Core Circadian Gene Variants on Glycemic Parameters and Insulin Resistance in Type 2 Diabetes: A Systematic Review. | Cureus | 2026 | 42504374 | PubTator, text mining | PubMed |
| Melatonin Promotes Human Hair Follicle Stem Cell Proliferation by Suppressing 5-AR: Implications for Treating Androgenetic Alopecia. | J Craniofac Surg | 2026 | 42441367 | PubTator, text mining | PubMed |
| Hierarchical Disruption of the Tryptophan-Melatonin Axis Contributes to Glioma Progression Through AKT/ERK/STAT3 Signalling. | J Cell Mol Med | 2026 | 42286740 | PubTator, text mining | PubMed |
| Epigenetic Shifts in MTNR1A, MTNR1B and Fn14 and Their Links to Preeclampsia Risk. | Ann Hum Genet | 2026 | 42257518 | PubTator, text mining | PubMed |
| Melatonin receptor signaling in human pathologies: from molecular mechanisms to therapeutic targets. | Function (Oxf) | 2026 | 42139078 | PubTator, text mining | PubMed |
| Melatonin maintains human umbilical vein endothelial cells function through potential regulation of the AKT-mTOR signaling pathway involving SIRT7 in preeclampsia. | Mol Cell Endocrinol | 2026 | 42097527 | PubTator, text mining | PubMed |
| Melatonin Receptor 1 and Melatonin Receptor 2 Expression During Human Kidney Development and Their Association with CAKUT. | J Dev Biol | 2026 | 42029548 | PubTator, text mining | PubMed |
| Melatonin ameliorates TNFα-induced oral epithelial cell inflammation via Keap1-Nrf2 axis modulation. | Am J Transl Res | 2026 | 42007122 | PubTator, text mining | PubMed |
| Ferroptosis in Parkinson's disease: a review of molecular mechanisms and emerging therapeutic strategies. | Front Neurosci | 2026 | 41799880 | PubTator, text mining | PubMed |
1 to 10 of 747
See all 747 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/4543
GET https://conductscience.org/api/genes/v1/4543/patents?page=2